Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer
Anticancer Research · 2024
DOI: 10.21873/anticanres.16917 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Shinsuke Hara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Osaka University Hospital, Suita, Japan. Hauptthemen laut MEDLINE: Frontotemporal Dementia, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Osaka University Hospital, Suita, Japan.
- Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan.
- Department of Pharmacy, Osaka University Hospital, Suita, Japan; ikemurak@hp-drug.med.osaka-u.ac.jp.
Zitieren
APA
Hara, S., Sakai, D., Ikemura, K., Shintani, T., Yamamoto, T., Satoh, T., & Okuda, M. (2024). Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.16917
Vancouver
Hara S, Sakai D, Ikemura K, Shintani T, Yamamoto T, Satoh T, et al. Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer. Anticancer Research. 2024. doi:10.21873/anticanres.16917
BibTeX
@article{Hara2024,
author = {Hara, Shinsuke and Sakai, Daisuke and Ikemura, Kenji and Shintani, Takuya and Yamamoto, Tomoya and Satoh, Taroh and Okuda, Masahiro},
title = {Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.16917}
}
EUVIMED